IN8BIO INC
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
INAB$0.94+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity
(In thousands, except share data)
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2021 | 18,781,242 | $2 | $70,872 | $(32,691) | $38,183 |
| Issuance of common stock, net of issuance costs of $919 | 5,706,686 | 1 | 9,541 | — | 9,542 |
| Stock options exercises | 57,229 | — | 61 | — | 61 |
| Stock-based compensation expense | — | — | 3,467 | — | 3,467 |
| Net loss | — | — | — | (28,521) | (28,521) |
| Balance at December 31, 2022 | 24,545,157 | 3 | 83,941 | (61,212) | 22,732 |
| Issuance of common stock, net of issuance costs of $445 | 7,492,580 | — | 14,380 | — | 14,380 |
| Issuance of private placement common stock, net of issuance costs of $729 | 11,249,588 | 1 | 10,183 | — | 10,184 |
| Issuance of private placement warrants, net of issuance costs of $234 | — | — | 3,278 | — | 3,278 |
| Stock-based compensation expense | — | — | 4,370 | — | 4,370 |
| Net loss | — | — | — | (30,007) | (30,007) |
| Balance at December 31, 2023 | 43,287,325 | $4 | $116,152 | $(91,219) | $24,937 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.